Prognostic Value of the Platelet-lymphocyte Ratio for Glioblastoma: A Systematic Review

Bispo, Rafaela Góes; Siqueira, Izabella Fernanda Bastos; Oliveira, Bruno Felipe Santos de; Fernandes, Camila Emanuele Moreira; Figueiredo, Lais Almeida; Cintra, Leandro Pinheiro; Oliveira, Adilson de

doi:10.1016/j.wneu.2023.04.086

Cited by 7 publications

(4 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognostic/predictive power of NLR may be further improved by combining NLR assessment with other biomarkers. According to recent meta-analyses and systematic reviews, absolute/total lymphocyte count (ALC/TLC, especially post-treatment) ( 321 ), platelet-to-lymphocyte ratio (PLR) ( 133 , 322 ), lymphocyte-to-monocyte ratio (LMR) ( 323 ), systemic immune-inflammation index (SII), calculated by platelet count×neutrophil count/lymphocyte count ( 129 , 324 ), and systemic immune response index (SIRI), calculated by neutrophil count×monocyte/lymphocyte count ( 325 – 327 ) are the emerging prognostic factors in glioblastoma/glioma. In a retrospective study, Yang et al.…”

Section: Future Directionsmentioning

confidence: 99%

Systemic and local immunosuppression in glioblastoma and its prognostic significance

Stepanenko,

Sosnovtseva,

Valikhov

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The effectiveness of tumor therapy, especially immunotherapy and oncolytic virotherapy, critically depends on the activity of the host immune cells. However, various local and systemic mechanisms of immunosuppression operate in cancer patients. Tumor-associated immunosuppression involves deregulation of many components of immunity, including a decrease in the number of T lymphocytes (lymphopenia), an increase in the levels or ratios of circulating and tumor-infiltrating immunosuppressive subsets [e.g., macrophages, microglia, myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs)], as well as defective functions of subsets of antigen-presenting, helper and effector immune cell due to altered expression of various soluble and membrane proteins (receptors, costimulatory molecules, and cytokines). In this review, we specifically focus on data from patients with glioblastoma/glioma before standard chemoradiotherapy. We discuss glioblastoma-related immunosuppression at baseline and the prognostic significance of different subsets of circulating and tumor-infiltrating immune cells (lymphocytes, CD4+ and CD8+ T cells, Tregs, natural killer (NK) cells, neutrophils, macrophages, MDSCs, and dendritic cells), including neutrophil-to-lymphocyte ratio (NLR), focus on the immune landscape and prognostic significance of isocitrate dehydrogenase (IDH)-mutant gliomas, proneural, classical and mesenchymal molecular subtypes, and highlight the features of immune surveillance in the brain. All attempts to identify a reliable prognostic immune marker in glioblastoma tissue have led to contradictory results, which can be explained, among other things, by the unprecedented level of spatial heterogeneity of the immune infiltrate and the significant phenotypic diversity and (dys)functional states of immune subpopulations. High NLR is one of the most repeatedly confirmed independent prognostic factors for shorter overall survival in patients with glioblastoma and carcinoma, and its combination with other markers of the immune response or systemic inflammation significantly improves the accuracy of prediction; however, more prospective studies are needed to confirm the prognostic/predictive power of NLR. We call for the inclusion of dynamic assessment of NLR and other blood inflammatory markers (e.g., absolute/total lymphocyte count, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, systemic immune-inflammation index, and systemic immune response index) in all neuro-oncology studies for rigorous evaluation and comparison of their individual and combinatorial prognostic/predictive significance and relative superiority.

show abstract

Section: Future Directionsmentioning

confidence: 99%

Systemic and local immunosuppression in glioblastoma and its prognostic significance

Stepanenko,

Sosnovtseva,

Valikhov

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The overexpression of NFE2L2, NOX4 and PD-L1 genes correlates with such immunosuppression phenotype [161]. Simple blood count indices of immunoinflammation, such as the ratio of platelets to lymphocytes, may also contribute to the prognosis of HGG patients [162].…”

Section: Modelling the Prognosis Of Hggmentioning

confidence: 99%

Advancements in Image-Based Models for High-Grade Gliomas Might Be Accelerated

Frosina

2024

Cancers

View full text Add to dashboard Cite

The first half of 2022 saw the publication of several major research advances in image-based models and artificial intelligence applications to optimize treatment strategies for high-grade gliomas, the deadliest brain tumors. We review them and discuss the barriers that delay their entry into clinical practice; particularly, the small sample size and the heterogeneity of the study designs and methodologies used. We will also write about the poor and late palliation that patients suffering from high-grade glioma can count on at the end of life, as well as the current legislative instruments, with particular reference to Italy. We suggest measures to accelerate the gradual progress in image-based models and end of life care for patients with high-grade glioma.

show abstract

“…A number of hematological indicators have been reported to be highly predictive of cancer patient prognosis in recent years, such as the neutrophil-to-lymphocyte ratio (NLR) [ 10 ], platelet-to-lymphocyte ratio (PLR) [ 11 ], systemic immune-inflammation index (SII) [ 12 ], and lymphocyte-to-monocyte ratio (LMR) [ 13 ]. For example, a review involving 11 studies showed that PLR could be a useful marker to aid in the prognosis of GBM [ 14 ]. Another important systematic review indicated that the NLR was a cost-effective and low-cost tool that was associated with tumor grading and overall survival (OS) in patients with glioma [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with glioma: a meta-analysis

Wang,

Xu,

Zhang

2023

BMC Med

View full text Add to dashboard Cite

Background Many studies have explored the prognostic role of the lymphocyte-to-monocyte ratio (LMR) in patients with glioma, but the results have been inconsistent. We therefore conducted the current meta-analysis to identify the accurate prognostic effect of LMR in glioma. Methods The electronic databases of PubMed, Web of Science, Embase, and Cochrane Library were thoroughly searched from inception to July 25, 2023. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to estimate the prognostic role of LMR for glioma. Results A total of 16 studies comprising 3,407 patients were included in this meta-analysis. A low LMR was significantly associated with worse overall survival (OS) (HR = 1.35, 95% CI = 1.13–1.61, p = 0.001) in glioma. However, there was no significant correlation between LMR and progression-free survival (PFS) (HR = 1.20, 95% CI = 0.75–1.91, p = 0.442) in glioma patients. Subgroup analysis indicated that a low LMR was significantly associated with inferior OS and PFS in glioma when using a cutoff value of ≤ 3.7 or when patients received mixed treatment. Conclusions This meta-analysis demonstrated that a low LMR was significantly associated with poor OS in glioma. There was no significant correlation between LMR and PFS in glioma patients. The LMR could be a promising and cost-effective prognostic biomarker in patients with glioma in clinical practice.

show abstract

Prognostic Value of the Platelet-lymphocyte Ratio for Glioblastoma: A Systematic Review

Cited by 7 publications

References 48 publications

Systemic and local immunosuppression in glioblastoma and its prognostic significance

Systemic and local immunosuppression in glioblastoma and its prognostic significance

Advancements in Image-Based Models for High-Grade Gliomas Might Be Accelerated

Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with glioma: a meta-analysis

Contact Info

Product

Resources

About